Recent successes of tissue bioengineering in ophthalmology highlighted

Article

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Dr. Ellis-Behnke and his team at MIT conducted in vivo experiments in young and adult hamsters. After making a deep cut in the superior colliculus, the researchers injected a clear substance containing a self-assembling material made of peptides. This serves as a matrix for new cell growth. The researchers observed new axon growth first in young animals, then carried out a similar experiment in adults in a way that removed all visually-guided orienting behavior, Dr. Ellis-Behnke said.

Six weeks after the cut was made, the researchers began testing the animals and found complete regeneration and functional vision in all but two of the treated animals. In those two, the lack of improvement apparently was due to surgical error, Dr. Ellis-Behnke said. While the animals displayed some signs of healing, it was insufficient to drive their behavior.

In separate experiments, Dr. Ellis-Behnke and colleagues showed that axon growth could be seen in live animals.

Ultimately, they hope to apply these findings on self-assembling peptides and axon growth to humans, Dr. Ellis-Behnke concluded.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.